CASPAR is a Phase 2b study that is currently recruiting in Newcastle, Plymouth and London with the aim of investigating the efficacy and safety of three fixed doses of BEN2001 (0.5, 1 and 3 mg/d) compared to placebo for the treatment of excessive daytime sleepiness (EDS) in people living with Parkinson’s disease. More information, inclusion and exclusion criteria can be found here.
“Those who experience EDS report a significant impact on quality of life and that it inhibits an individual’s ability to socialise, drive, work and do normal everyday activities. A short survey run by PM in 2017 revealed that EDS is “overpowering”, coming on suddenly, “like a battery running out of charge” and “it seriously affects my movements, speech and social interactions.” Understanding if BEN2001 could help those who experience EDS is an important research question,” said Helen Matthews, Deputy CEO of The Cure Parkinson’s Trust.
- Subjects of either sex aged 50 to 80 years *Subjects with previous diagnosis of Parkinson’s disease (following the UK Parkinson’s disease society brain bank clinical diagnostic criteria)*
- Subjects capable of understanding and complying with protocol requirements
- Subjects with medical history of excessive daytime sleepiness
- For exclusion criteria please click here
I’d like to take part – who is running the study? Who should I contact?